128
Views
22
CrossRef citations to date
0
Altmetric
Review

Prevention of Haemophilus influenzae type b disease: past success and future challenges

, &
Pages 819-827 | Published online: 09 Jan 2014

References

  • Heath PT, McVernon J. The UK Hib vaccine experience. Arch. Dis. Child 86, 396–399 (2002).
  • Centers for Disease Control and Prevention, National Immunization Program. The epidemiology and prevention of vaccine-preventable diseases: The Pink Book, 8th Edition. The Public Health Foundation, Waldorf, MD, USA, January (2005).
  • Wenger JD, Pierce R, Deaver K et al. Invasive Haemophilus influenzae disease: a population-based evaluation of the role of capsular polysaccharide serotype. Haemophilus influenzae study group. J. Infect. Dis. 165(Suppl. 1), S34–S35 (1992).
  • Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae Type b conjugate vaccines. Immunology 113, 163–174 (2004).
  • Barbour ML. Conjugate vaccines and the carriage of Haemophilus influenzae type b. Emerg. Infect. Dis. 2(3), 176–182 (1996).
  • Jain A, Kumar P, Awasthi S. High Nasopharyngeal carriage of drug-resistant Streptococcus pneumoniae and Haemophilus influenzae in north Indian school children. Trop. Med. Int. Health 10, 234–239 (2005).
  • Olsen SJ, Dejsirilert S, Sangsuk L, Chunsutiwat S, Dowell SF. Frequent Haemophilus influenzae type b colonization in rural Thailand. Pediatr. Inf. Dis. J. 24, 739–742 (2005).
  • Sung RY, Ling JM, Fung SM et al. Carriage of Haemophilus influenzae and Streptococcus pneumoniae in healthy Chinese and Vietnamese children in Hong Kong. Acta. Paediatr. 84, 1262–1267 (1995).
  • Alcon A, Fabregas N, Torres A. Pathophysiology of pneumonia. Clin. Chest Med. 26, 39–46 (2005).
  • D’Angio CT, Froehlke RG, Plank GA et al. Long-term outcome of Haemophilus influenzae meningitis in Navajo Indian children. Arch. Pediatr. Adolesc. Med. 149(9), 1001–1008 (1995).
  • Wenger JD. Epidemiology of Haemophilus influenzae type b disease and impact of Haemophilus influenzae type b conjugate vaccines in the United States and Canada. Pediatric. Inf. Dis. J. 17(9), S132–S136 (1998).
  • Bijlmer HA. Worldwide epidemiology of Haemophilus influenzae meningitis; industrialized versus non-industrialized countries. Vaccine 9, S5–S9 (1991).
  • Kilpatrick ME, Mikhail IA, Girgis NI. Negative cultures of cerebrospinal fluid in partially treated bacterial meningitis. Trop. Geograph. Med. 39, 345–349 (1987).
  • Vuori-Holopainen E, Peltola H. Reappraisal of lung tap: review of an old method for better etiologic diagnosis of childhood pneumonia. Clin. Infect. Dis. 32(5), 715–726 (2001).
  • Isaacs D. Problems in determining the etiology of community-acquired childhood pneumonia. Pediatr. Infect. Dis. J. 8, 143–148 (1989).
  • Baselski VS, Wunderink RG. Bronchoscopic diagnosis of pneumonia. Clin. Microbiol. Rev. 7(4), 533–558 (1994).
  • Manary MJ, Lehmann D, Michael A et al. Antigenuria in healthy Papua New Guinean children with nasal Haemophilus influenzae type b carriage. Ann. Trop. Paediatr. 13(4), 385–389 (1993).
  • Adegbola RA, Mulholland EK, Secka O, Jaffar S, Greenwood BM. Vaccination with a Haemophilus influenzae type b conjugate vaccine reduces oropharyngeal carriage of H. influenzae type b among Gambian children. J. Infect. Dis. 177, 1758–1761 (1998).
  • Gessner BD, Sutanto A, Linehan M et al. Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomized vaccine-probe trial. Lancet 365, 43–52 (2005).
  • Mulholland K, Hilton S, Adegbola R et al. Randomized trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine for prevention of pneumonia and meningitis in Gambian infants. Lancet 349, 1191–1197 (1997).
  • Levine OS, Lagos R, Munoz A et al. Defining the burden of pneumonia in children preventable by vaccination against Haemophilus influenzae type b. Pediatr. Infect. Dis. J. 18, 1060–1064 (1999).
  • Kessler A, Wetmore RF, Marsh RR. Childhood epiglottitis in recent years. Int. J. Ped. Oto. 25, 155–162 (1993).
  • Hanna J. The epidemiology of invasive Haemophilus influenzae infections in children under 5 years of age in the Northern Territory: a three-year study. Med. J. Aust. 152, 234–240 (1990).
  • Ward JI, Lum KW, Hall DB, Silimperi DR, Bender TR. Invasive Haemophilus influenzae type b disease in Alaska: background epidemiology for a vaccine efficacy trial. J. Infect. Dis. 153, 17–26 (1986).
  • Ferreccio C, Ortiz E, Astroza L, Rivera C, Clemens J, Levine MM. A population based retrospective assessment of the disease burden resulting from invasive Haemophilus influenzae in infants and young children in Santiago, Chile. Pediatr. Infect. Dis. J. 9, 488–494 (1990).
  • Adams WG, Deaver KA, Cochi SL et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA 269(2), 221–226 (1993).
  • Bisgard KM, Kao A, Leake J, Strebel PM, Perkins BA, Wharton M. Haemophilus Influenzae invasive disease in the United States, 1994–1995: near disappearance of a vaccine-preventable childhood disease. Emerg. Infect. Dis. 4, 229–237 (1998).
  • Cochi SL, Broome CV, Hightower AW. Immunization of US children with Haemophilus influenzae type b polysaccharide vaccine: a cost-effectiveness model of strategy assessment. JAMA 253, 521–529 (1985).
  • Yost GC, Kaplan AM, Bustamante R, Ellison C, Hargrave AF III, Randall DL. Bacterial meningitis in Arizona American Indian children. Am. J. Dis. Child. 140, 943–946 (1986).
  • Coulehan JL, Michaels RH, Hallowell C, Schults R, Welty TK, Kuo JS. Epidemiology of Haemophilus influenzae type b disease among Navajo Indians. Public Health Rep. 99, 404–409 (1984).
  • Gilbert GL. Epidemiology of Haemophilus influenzae type b disease in Australia and New Zealand. Vaccine 9, S10–S13 (1991).
  • Watt JP, Levine OS, Santosham M. Global reduction of Hib disease: what are the next steps? Proceedings of the meeting Scottsdale, Arizona, September 22–25, 2002. J. Pediatr. 143, S163–S187 (2003).
  • Global programme for vaccines, immunization (GPV). The WHO position paper on Haemophilus influenzae type b conjugate vaccines. Wkly Epidemiol. Rec. 73(10), 64–68 (1998).
  • Peltola H. Haemophilus influenzae type b disease and vaccination in Europe: lessons learned. Pediatr. Infect. Dis. J. 17(9), S126–S132 (1998).
  • Saha SK, Baqui AH, Darmstadt GL et al. Invasive Haemophilus influenzae type b diseases in Bangladesh, with increased resistance to antibiotics. J. Pediatr. 146, 227–233 (2005).
  • Olowokure B, Spencer NJ, Hawker JI, Blair I, Smith RL. Invasive Haemophilus influenzae disease: an ecologic study of sociodemographic factors before and after the introduction of the Hib conjugate vaccine. Eur. J. Epidemiol. 18(4), 363–367 (2003).
  • Zielinski A, Kwon CB, Tomaszunas-Blaszczyk J, Magdzik W, Bennett JV. Risk of Haemophilus influenzae type b meningitis in Polish children varies directly with number of siblings: possible implications for vaccination strategies. Eur. J. Epidemiol. 18(9), 917–922 (2003).
  • Silfverdal SA, Bodin L, Hugosson S et al. Protective effect of breastfeeding on invasive Haemophilus influenzae infection: a case-control study in Swedish preschool children. Int. J. Epidemiol. 26(2), 443–450 (1997).
  • Takala AK, Eskola J, Palmgren J et al. Risk factors of invasive Haemophilus influenzae type b disease among children in Finland. J. Pediatr. 115(5 Pt 1), 694–701 (1989).
  • Jordans JZ, Slack MP. Haemophilus influenzae: Then andnow. Eur. J. Clin. Microbiol. Infect. Dis. 14, 935–948 (1995).
  • Jones ME, Karlowsky JA, Blosser-Middleton R et al. Apparent plateau in β-lactamase production among clinical isolates of Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the LIBRA surveillance initiative. Int. J. Antimicrob. Agents. 19, 119–123 (2002).
  • Sow SO, Diallo S, Campbell JD et al. Burden of invasive disease caused by Haemophilus influenzae type b in Bamako, Mali: impetus for routine infant immunization with conjugate vaccine. Pediatr. Infect. Dis. J. 24(6), 533–537 (2005).
  • Kwak YH, Jung HS, Park SE et al. Serotypes and antimicrobial susceptibility in clinical isolates of Haemophilus influenzae from Korean children in prevaccination era. J. Korean Med. Sci. 15(6), 616–622 (2000).
  • Campos J, Hernando M, Roman F et al. Analysis of invasive Haemophilus influenzae infections after extensive vaccination against H. influenzae type b. J. Clin. Microbiol. 42(2), 524–529 (2004).
  • De Andrade ALSS, Brandileone MC, di Fabio JL et al. Haemophilus influenzae resistance in Latin America: systematic review of surveillance data. Microb. Drug Resist. 7(4), 403–411 (2001).
  • Zanella RC, Casagrande ST, Bokermann S, Almeida SCG, Brandileone MCC. Characterization of Haemophilus influenzae isolated from invasive disease in Brazil from 1990 to 1999. Microb. Drug Resist. 8(1), 67–72 (2002).
  • Peltola H, Kayhty H, Sivonen A et al. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics 60, 730–737 (1977).
  • Santosham M. Prevention of Haemophilus influenzae type b disease. Vaccine 11(1), S52–S57, (1993).
  • Santosham M, Reid R, Ambrosino DM et al. Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin. N. Engl. J. Med. 317(15), 923–929 (1987).
  • Ward J, Brenneman G, Letson GW, Heyward WL, Alaska H. Influenzae vaccine study group: limited efficacy of a Haemophilus Influenzae type b conjugate vaccine in Alaska native infants. N. Engl. J. Med. 323, 1393–1401 (1990).
  • Eskola J, Kayhty H, Takala AK et al. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N. Engl. J. Med. 323 1381–1387 (1990).
  • Black SB, Shinefield HR, Fireman B, Hiatt R, Polen M, Vittinghoff E. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. Pediatr. Infect. Dis. J. 10, 97–104 (1991).
  • Santosham M, Wolff M, Reid R et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N. Engl. J. Med. 324, 1767–1772 (1991).
  • Booy R, Hodgson S, Carpenter L et al. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T. Lancet 344, 362–366 (1994).
  • John TJ, Samuel R. Herd immunity and herd effect: new insights and definitions. Eur. J. Epidemiol. 16, 601–606 (2000).
  • Gallo G, degli Atti MLC, Cerquetti M, Piovesan C, Tozzi AE, Slmaso S. Impact of a regional Hib vaccination programme in Italy. Vaccine 20, 993–995 (2002).
  • Perdue DG, Bulkow LR, Gellin BG et al. Invasive Haemophilus influenzae disease in Alaskan residents aged 10 years and older before and after infant vaccination programs. JAMA 283, 3089–3094 (2000).
  • Makela PH, Kayhty H, Tuija L et al. Long-term persistence of immunity of immunization with Haemophilus influenzae type b conjugate vaccine. Vaccine 22, 287–292 (2003).
  • Moulton LH, Chung S, Croll J, Reid R, Weatherholtz RC, Santosham M. Estimation of the indirect effect of Haemophilus influenzae type b conjugate vaccine in an American Indian population. Int. J. Epidemiol. 29(4), 753–756 (2000).
  • Adegbola SA, Secka O, Lahai G et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunization with a Hib conjugate vaccine: a prospective study. Lancet 366(9480), 144–150 (2005).
  • Zielen S, Ahrens P, Hofmann D. Efficacy of Hib vaccine. Lancet 344, 828 (1994).
  • Reinert P, Liwartowski A, Dabernat H, Guyot C, Boucher J, Carrere C. Epidemiology of Haemophilus influenzae type b disease in France. Vaccine 11, S38–S42 (1993).
  • Lagos R, Horowitz I, Toro J et al. Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. 15, 216–222 (1996).
  • Kalies H, Verstraeten T, Grote V et al. Four and one-half year follow-up of the effectiveness of diphtheria-tetanus toxoids-accellular pertussis/Haemophilus influenzae type b and diphtheria-tetanus toxoids-accellular pertussis-inactivated poliovirus/H. influenzae type b combination vaccines in Germany. Pediatr. Infec. Dis. J. 23(10), 944–950 (2004).
  • Petersen K, Bulkow L, McMahon B, Wainwright R, Peters H. Immunogenicity of a combined Hepatitis B and Haemophilus influenzae type b conjugate vaccine in Alaskan native infants. Int. J. Circumpolar Health 57(Suppl. 1), 285–292 (1998).
  • Daum RS. Efficacy of the combined diphtheria-tetanus toxoids -pertussis–Haemophilus conjugate vaccine. Pediatr. Infec. Dis. J. 14(7), 640–641 (1995).
  • Eskola J, Olander R, Hovi T, Litmanen L, Peltola S, Kayhty H. Randomised trial of the effect of co-administration with acellular pertussis DTP vaccine on immunogenicity of Haemophilus influenzae type b conjugate vaccine. Lancet 348, 1688–1692 (1996).
  • McVernon J, Andrews N, Slack MP, Ramsay ME. Risk of vaccine failure after Haemophilus influenzae type b (Hib) combination vaccines with acellular pertussis. Lancet 361(9368), 1521–1523 (2003).
  • Goldblatt D, Richmond P, Millard E, Thornton C, Miller E. The induction of immunologic memory after vaccination with Haemophilus influenzae type b conjugate and acellular pertussis-containing diphtheria, tetanus, and pertussis vaccine combination. J. Infect. Dis. 180, 538–541 (1999).
  • Fernández J, Balter S, Feris J et al. Randomized trial of the immunogenicity of fractional dose regimens of PRP-T Haemophilus influenzae type b conjugate vaccine. Am. J. Trop. Med. Hyg. 62, 485–490 (2000).
  • Lagos R, Valenzuala MT, Levine OS et al. Economizing vaccination against Haemophilus influenzae type b: a randomized trial of the immunogenicity of fractional- and two-dose regimens. Lancet 351, 1472–1476 (1998).
  • Centers for Disease Control and Prevention. Progress toward elimination of Haemophilus influenzae type b invasive disease among infants and children - United States, 1998–2000. Morbidity and Mortality Weekly Report 51(11), 234–247 (2002).
  • Millar EV, O’Brien KL, Watt JP et al. Epidemiology of invasive Haemophilus influenzae type a disease among Navajo and White Mountain Apache children, 1988–2003. Clin. Infect. Dis. 40, 823–830 (2005).
  • World Health Organization. Estimating the local burden of Haemophilus influenzae type b (Hib) disease preventable by vaccination: a rapid assessment tool. Department of Vaccines and Biologicals. WHO/V&B/01.27. World Health OrganizationGeneva, Switzerland (2001).
  • Russell FM, Carapetis JR, Mansoor O et al. High incidence of Haemophilus influenzae type b infection in children in Pacific Island countries. Clin. Infect. Dis. 37, 1593–1599 (2003).
  • Campagne G, Garba A, Schuchat A et al. Response to conjugate Haemophilus influenzae B vaccine among infants in Niamey, Niger. Am. J. Trop. Med. Hyg. 59(5), 837–842 (1998).
  • Weekly Epidemiological Record. World Health Organization review panel on Haemophilus influenzae type b (Hib) disease burden in Bangladesh, Indonesia and other Asian countries, Bangkok, 28–29 January 2004. 79(18), 173–180 (2004).
  • Mitchell V, Walker D, Zuber P, Lydon P, Ahun M. Evidenced-based decision making about Hib vaccination. Lancet 365, 936–937 (2005).
  • World Health Organization. Vaccine preventable diseases and immunization programme: programme report and future initiatives 2001–2005. Geneva, Switzerland (2005).
  • Peltola H, Eskola J, Kayhty H, Takala AK, Makela PH. Clinical comparison of the Haemophilus influenzae type b polysaccharide-diphtheria toxoid and the olidosaccharide-CRM197 protein vaccines in infancy. Arch. Pediatr. Adolesc. Med. 148, 620–625 (1994).

Websites

  • Haemophilus influenzae Type b Disease Information. The Global Alliance for Vaccines and Immunization. http://www.vaccinealliance.org/General_Information/Immunization_informa/Diseases_Vaccines/haemoph.php (Accessed November 2005)
  • 14th GAVI Board Meeting, Abujua, Nigeria, 4–5 December 2004, Summary Report. The Global Alliance for Vaccines and Immunization. http://www.vaccinealliance.org/Board/Board_Reports/14brd_HibTF_recs.php (Accessed November 2005)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.